Table 2 Breast Cancer Related Cumulative Charges by BRCA Status and Charge Type
From: Estimation of healthcare‐related charges in women with BRCA mutations and breast cancer
| Health care charges ($US) | Overall n=816 | BRCAm n=134 | BRCAwt n=682 | BRCAm vs. BRCAwt | |||
|---|---|---|---|---|---|---|---|
|
Mean (SD) | Median (IQR) |
Mean (SD) | Median (IQR) |
Mean (SD) | Median (IQR) | p-value | |
| Facilities/ Technical |
29,090 (26,802)33.8%a |
24,027 (34,043) |
35,130 (28,878) 40.5% |
33,037 (42,145) |
27,903 (26,234) 32.5% |
22,458 (32,529) | 0.01 |
| Physician/ Professional |
15,615 (13,126), 18.2% |
12,441 (17,669) |
16,207 (12,198), 18.7% |
15,624 (18,967) |
15,498 (13,306) 18.1% |
11,908 (16,906) | 0.25 |
| Pharmacy |
41,277 (69,308) 48.0% |
9,313 (58,716) |
35,352 (51,919) 40.8% |
11,379 (54,399) |
42,442 (72,209) 49.4% |
8,930 (59,659) | 0.65 |
|
Total Anticancer Treatment |
24,616 (56,779) |
2,018 (15,804) |
16,821 (38,088) |
2,756 (14,673) |
26,148 (59,671) |
1,824 (15,995) | 0.72 |
| Other Medication(s) |
16,661 (24,471) |
2,911 (27,834) |
18,531 (24,484) |
6,035 (30,729) |
16,294 (24,470) |
2,609 (26,434) | 0.19 |
| Clinical Trial |
56 (347) |
0 (0) |
89 (621) |
0 (0) |
49 (262) |
0 (0) | 0.93 |
| Chemotherapy |
7,171 (14,088) |
1,372 (6,575) |
8,439 (14,791) |
2,344 (9,463) |
6,922 (13,944) |
1,180 (6,124) | 0.13 |
| Hormonal Therapy |
890 (5,521) |
0 (0) |
769 (4,334) |
0 (0) |
914 (5,728) |
0 (0) | 0.53 |
| Biologic Medicine |
16,499 (50,091) |
0 (0) |
7,524 (30,898) |
0 (0) |
18,262 (52,891) |
0 (0) | 0.02 |
| Chemotherapy Administration |
0 (5) |
0 (0) |
1 (7) |
0 (0) |
0 (5) |
0 (0) | NA |
| Total Charges |
85,982 (94,087) |
55,230 (94,787) |
86,689 (75,937) |
65,414 (95,894) |
85,843 (97,304) |
54,635 (94,085) | 0.19 |